





Robert Greene Sterne Jorge A. Goldstein David K.S. Comwell Robert W. Esmond Tracy-Gene G. Durkin Michael B. Ray Robert E. Sokohl Eric K. Steffe Michael Q. Lee Steven R. Ludwig John M. Covert Linda E. Horner Robert C. Millonig Donald J. Featherstone Timothy J. Shea, Jr Michael V. Messinger Judith U. Kim

Patrick E. Garrett
Jeffrey T. Helvey
Icldora L. Ellison
Thomas C. Fiala
Donald R. Banowit
Peter A. Jackman
Jeffrey S. Weaver
Brian J. Del Buono
Edward W. Yee
Vincent L. Capuano
Virgil Lee Beaston
Theodore A. Wood
Elizabeth J. Haanes
Joseph S. Ostroff
Frank R. Cottingham
Rae Lynn P. Guest
Daniel A. Klein
Jason D. Eisenberg

Michael D. Specht Tracy L. Muller Jon E. Wright LuAnne M. DeSantis Ann E. Summerfield Helene C. Carlson
<sup>1</sup> Cynthia M. Bouchez Timothy A. Doyle Gaby L. Longsworth Lori A. Gordon Laura A. Vogel Bryan S. Wade Bashir M.S. Ali Shannon A. Carroll Matthew E. Kelley Anbar F. Khal Michelle K. Holoubek Marsha A. Rose

Young Tan Christoph W. Blake ( James J. P John T. Ha Mark W. R Kevin W. N Registered Karen R. N Matthew Katrina Y Bryan L. Sl Robert A.

Young Tang Christopher J. Walsh W. Blake Coblentz\* James J. Pohl\* John T. Haran\* Mark W. Rygiel Kevin W. McCabe

Registered Patent Agents « Karen R. Markowicz Matthew J. Dowd Katrina Vüjian Pei Quach Bryan L. Skelton Robert A. Schwartzman Victoria S. Rutherford Simon J. Elliott Julie A. Heider Mita Mukheriee Scott M. Woodhouse Liliana Di Nola-Baron Peter A. Socarras Jeffrey K. Mills Danielle L. Letting Lori Brandes Steven C. Oppenheimer

Of Counsel Edward J. Kessler Kenneth C. Bass III Marvin C. Guthrie

\*Admitted only in Maryland \*Admitted only in Virginia •Practice Limited to Federal Agencies

October 4, 2006

WRITER'S DIRECT NUMBER: (202) 772-8856 INTERNET ADDRESS: KMCCABE@SKGF.COM

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450 Art Unit 1634

Attn: Mail Stop Amendment

Re:

U.S. Utility Patent Application

Application No. 10/797,164; Filed: March 9, 2004

For: Methods of Identifying Optimal Drug Combinations and

**Compositions Thereof** 

Inventors:

PFOST et al.

Our Ref:

2512.0030003/RWE/KWM

Sir:

Transmitted herewith for appropriate action are the following documents:

- 1. Information Disclosure Statement;
- 2. Form PTO/SB/08A one (1) page listing twenty-one (21) cited documents (US1-US17 and FP1-FP4);
- 3. Form PTO/SB/08B one (1) page listing one (1) cited document (NPL1); and
- 4. Return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

Sterne, Kessler, Goldstein & Fox PLLC. : 1100 New York Avenue, NW : Washington, DC 20005 : 202.371.2600 f 202.371.2540 : www.skgf.com

Commissioner for Patents October 4, 2006 Page 2

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Kevin W. McCabe Attorney for Applicants Registration No. 41,182

RWE/KWM/egw Enclosures

591401v1



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

PFOST et al.

Appl. No.: 10/797,164

Filed: March 9, 2004

For: Methods of Identifying Optimal

**Drug Combinations and Compositions Thereof** 

Confirmation No.: 4027

Art Unit: 1634

Examiner: Myers, C.J.

Atty. Docket: 2512.0030003/RWE/KWM

## **Information Disclosure Statement**

Mail Stop Amendment

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Sir:

Listed on accompanying IDS Forms are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98.

Copies of the documents **FP1-FP4** and **US1-US17** cited on the attached Form PTO/SB/08A, and **NPL1** cited on the attached Form PTO/SB/08B were cited by or submitted to the Office in an IDS that complies with 37 C.F.R. § 1.98(a)-(c) in Application No. 10/034,882, filed December 27, 2001, which is relied upon for an earlier filing date under 35 U.S.C. § 120. Thus, copies of these documents are not attached. 37 C.F.R. § 1.98(d).

It is expected that the examiner will review the prosecution and cited art in the parent application number 10/034,882 in accordance with MPEP 2001.06(b), and

indicate in the next communication from the office that the art cited in the earlier prosecution history has been reviewed in connection with the present application.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached IDS Forms based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits. No statement or fee is required.

It is respectfully requested that the Examiner initial and return a copy of the enclosed IDS Forms, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Kevin W. McCabe Attorney for Applicants Registration No. 41,182

Date: October 4, 2006

1100 New York Avenue, N.W. Washington, D.C. 20005-3934 (202) 371-2600

586480v1

OTPE 42006

Sheet

Substitute for form 1449A/PTO

Equivalent of Form PTO/SB/08A (07-06)
Approved for use through 09/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

of

(Use as many sheets as necessary)

(Use as many sneets as necessary)

Complete if Known

Application Number 10/797,164

Filling Date March 9, 2004

First Named Inventor Dale PFOST

Art Unit 1634

Examiner Name Myers, C.J.

Attorney Docket Number 2512.0030003/RWE/FRC

Examiner Initials*	Cite	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
	No.1	Number-Kind Code <sup>2 (If Known)</sup>	MM-DD-YYYY	Applicant of Cited Document		
	USI	4,623,619	11-18-1986	Owerbach, et al.		
	US2	4,683,195	07-28-1987	Mullis, et al.		
	US3	4,988,617	01-29-1991	Landegren, et al.		
	US4	5,422,253	06-06-1995	Dahlberg, et al.		
	US5	5,494,810	02-27-1996	Barany, et al.		
	US6	5,547,835	08-20-1996	Köster		
	US7	5,547,839	08-20-1996	Dower, et al.		
	US8	5,648,077	07-15-1997	Ostberg		
	US9	5,762,876	06-09-1998	Lincoln, et al.		
	US10	5,795,976	08-18-1998	Oefner, et al.		
	US11	5,846,546	12-08-1998	Hurwitz, et al.		
	US12	5,860,917	01-19-1999	Comanor, et al.		
	US13	5,888,819	03-30-1999	Goelet, et al.		
	US14	6,248,308 B1	06-19-2001	Rubin		
	US15	6,316,196 B1	11-13-2001	Morten		
	US16	6,593,092 B2	06-15-2003	Yu, et al.		
	US17	6,828,103 B2	12-07-2004	Herrington, et al.		

Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	t	
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)			T <sup>6</sup>	
	FP1	WO 97/13875	04-17-1997	Connaught Lab		
	FP2	WO 97/21833	06-19-1997	SmithKline Beecham, PLC		
	FP3	WO 99/11822	03-11-1999	Gene Logic, Inc.		
	FP4	WO 99/24571	05-20-1999	Curagen Corp.		
					•	

586455v1

Examiner	Date	
Signature	Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (07-06)

Approved for use through 09/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE and to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/TETO				Complete if Known		
				Application Number	10/797,164	
INFORMATION DISCLOSURE				Filing Date	March 9, 2004	
STATEMENT BY APPLICANT (Use as many sheets as necessary)			PLICANT	First Named Inventor	Dale PFOST	
				Art Unit	1634	
				Examiner Name	Myers, C.J.	
Sheet	1	of	1	Attorney Docket Number	2512.0030003/RWE/FRC	

Examiner Initials*  Cite No. Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), number(s), publisher, city and/or country where published  Nickerson,, et al., "PolyPhred: Automating the Detection and Genoty Single Nucleotide Substitutions Using Fluorescence-Based Resequent Nucleic Acids Res. 25:2745-2751 (1997)	volume-issue	T <sup>2</sup>
NPL1 Single Nucleotide Substitutions Using Fluorescence-Based Resequen	rping of icing,"	

586459v1

Examiner	Date	
Signature	Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.